本文選題：Src激酶家族 + 紫杉醇　； 參考：《中國(guó)藥科大學(xué)學(xué)報(bào)》2017年04期

【摘要】：Src激酶家族(SFK)在許多惡性腫瘤中均有高表達(dá),對(duì)于腫瘤細(xì)胞的惡性行為具有廣泛的調(diào)節(jié)作用。紫杉醇是臨床上廣泛應(yīng)用的化療藥物,但由于耐藥性的出現(xiàn)使其療效逐漸下降。本文就SFK的結(jié)構(gòu)與調(diào)節(jié)方式、紫杉醇耐藥產(chǎn)生的分子機(jī)制以及SFK調(diào)節(jié)紫杉醇耐藥的研究進(jìn)展進(jìn)行綜述,以期為基于紫杉醇的腫瘤治療方案提供新的治療參考依據(jù)。
[Abstract]:The Src kinase family is highly expressed in many malignant tumors and has a wide range of regulatory effects on the malignant behavior of tumor cells. Paclitaxel is a widely used chemotherapeutic drug in clinic. In this paper, the structure and regulation of SFK, the molecular mechanism of taxol resistance and the research progress of paclitaxel resistance regulation by SFK were reviewed in order to provide a new therapeutic reference for taxol based tumor therapy.
【作者單位】： 中國(guó)藥科大學(xué)江蘇省腫瘤發(fā)生與干預(yù)重點(diǎn)實(shí)驗(yàn)室;中國(guó)藥科大學(xué)天然藥物活性組分與藥效國(guó)家重點(diǎn)實(shí)驗(yàn)室;
【基金】：國(guó)家自然科學(xué)基金資助項(xiàng)目(No.81473231,No.81373449)~~
【分類(lèi)號(hào)】：R96
，

本文編號(hào)：1940069